[Articles] Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

Related Posts

• [Articles] Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

  These clinically meaningful results support the use of trastuzumab deruxtecan as second-line therapy in patients…

• Comparing Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in HER2+ Metastatic Breast Cancer Phase 3 Trial

  KEY TAKEAWAYS The DESTINY-Breast03 is a randomized, open-label, Phase 3 trial that evaluated the efficacy…

• HER2 in Trastuzumab Therapy: Prognostic Insights

  KEY TAKEAWAYS The study aimed to assess the prognostic impact of HER2 gene amplification in…